Evaluate

April 13, 2022

Takeover-driven resurgence fails to materialise for biotech

Deal making in biosimilars dominates a slow start to the year for biopharma M&A.

March 11, 2022

Alvotech settlement completes the list of Humira challengers

February 28, 2022

Another biosimilars retreat, this time from Viatris

January 28, 2022

Biogen sells its Bioepis stake bit by bit

October 01, 2021

US FDA approval tracker: September 2021

July 29, 2021

Insulin goes generic

May 14, 2021

Biogen’s big bet on gene therapy starts to go south

March 22, 2021

Biocryst joins the push against Soliris

July 02, 2020

Enbrel’s latest patent win? That’ll be $47bn